In case of male patients: either patient partners or patients themselves must use an effective method of avoiding pregnancy for at least 4 weeks prior to study drug administration, during study and up to 30 days after the last dose of study drug or till next chemotherapy cycle [clinicaltrials_resource:0f01b4ea8df330ac4e4f6c03d8fabab2]
exclusion criteria [clinicaltrials_vocabulary:exclusion-criteria]
inclusion criteria [clinicaltrials_vocabulary:inclusion-criteria]
In case of male patients: either patient partners or patients themselves must use an effective method of avoiding pregnancy for at least 4 weeks prior to study drug administration, during study and up to 30 days after the last dose of study drug or till next chemotherapy cycle [clinicaltrials_resource:0f01b4ea8df330ac4e4f6c03d8fabab2]
Bio2RDF identifier
0f01b4ea8df330ac4e4f6c03d8fabab2
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:0f01b4ea8df330ac4e4f6c03d8fabab2
identifier
clinicaltrials_resource:0f01b4ea8df330ac4e4f6c03d8fabab2
title
In case of male patients: eith ...... till next chemotherapy cycle
@en
type
label
In case of male patients: eith ...... 1b4ea8df330ac4e4f6c03d8fabab2]
@en